SynthesisClinical pharmacokinetics2020
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.
Synthesis in Clinical pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.Clinical pharmacology and therapeutics · 2021Pooled it
- Article
- Modulating Immune Response in Viral Infection for Quantitative Forecasts of Drug Efficacy.Pharmaceutics · 2023Review
- Optimizing antiviral therapy for COVID-19 with learned pathogenic model.Scientific reports · 2022Article
- Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.bioRxiv : the preprint server for biology · 2022Article
- Mega randomized clinical trials: a definitive solution or a double-edged sword?European journal of clinical pharmacology · 2022Article
- Scoping insight on antiviral drugs against COVID-19.Arabian journal of chemistry · 2021Review
- Review
- In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.The Journal of antimicrobial chemotherapy · 2021Article
- SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.European journal of pharmacology · 2021Article
- Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.CNS drugs · 2021Review
- [Antineoplasic drug repurposing in hematology for COVID-19 treatment].Bulletin du cancer · 2021Article
- Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.Cardiovascular drugs and therapy · 2021Review
- Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.Drugs in R&D · 2021Review
- Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2020Review
- How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.Acta bio-medica : Atenei Parmensis · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 10 countries.
Funding
Abstract
There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.